相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database
Dong-Sook Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Effect of statins use on risk and prognosis of breast cancer: a meta-analysis
Guodong Zhao et al.
ANTI-CANCER DRUGS (2022)
Role of β2-adrenergic receptors in chronic obstructive pulmonary disease
Ailin Yang et al.
LIFE SCIENCES (2021)
Pathway-Based Drug-Repurposing Schemes in Cancer: The Role of Translational Bioinformatics
Enrique Hernandez-Lemus et al.
FRONTIERS IN ONCOLOGY (2021)
Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
Mayu Hosio et al.
SCIENTIFIC REPORTS (2021)
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Yao Zhao et al.
PROTEIN & CELL (2021)
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
R. Caparica et al.
ESMO OPEN (2021)
A high-throughput screen identifies inhibitors of lung cancer stem cells
Xiaofei She et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
G protein-coupled receptors: structure- and function-based drug discovery
Dehua Yang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer
Rafael Caparica et al.
CLINICAL BREAST CANCER (2020)
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
β-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis
Chaoran Li et al.
BIOSCIENCE REPORTS (2020)
Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions
Eleni Sertedaki et al.
CELLS (2020)
Advances in G protein-coupled receptor high-throughput screening
Emily A. Yasi et al.
CURRENT OPINION IN BIOTECHNOLOGY (2020)
Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth
Cristina Nuevo-Tapioles et al.
NATURE COMMUNICATIONS (2020)
Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
Zheng Yao Low et al.
VIRUSES-BASEL (2020)
Association Between Statin Use and Prognosis of Breast Cancer: A Meta-Analysis of Cohort Studies
Hui Lv et al.
FRONTIERS IN ONCOLOGY (2020)
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhe Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
High-Throughput Screening Identified Compounds Sensitizing Tumor Cells to Glucose Starvation in Culture and VEGF Inhibitors In Vivo
Ran Marciano et al.
CANCERS (2019)
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
Patrycja Nowak-Sliwinska et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018)
Sayyed Mohammad Ismail Mahboubi Rabbani et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Drug repurposing: a promising tool to accelerate the drug discovery process
Vineela Parvathaneni et al.
DRUG DISCOVERY TODAY (2019)
Improving the odds of drug development success through human genomics: modelling study
Aroon D. Hingorani et al.
SCIENTIFIC REPORTS (2019)
GPCRs profiling and identification of GPR110 as a potential new target in HER2+breast cancer
Raksha R. Bhat et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Pharmacogenomics of GPCR Drug Targets
Alexander S. Hauser et al.
CELL (2018)
The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development
Tohru Takebe et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery
Nathan P. Coussens et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Krishna Sriram et al.
MOLECULAR PHARMACOLOGY (2018)
Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States
Dongya Jia et al.
CELLS (2018)
Review of Drug Repositioning Approaches and Resources
Hanqing Xue et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
A review of network-based approaches to drug repositioning
Maryam Lotfi Shahreza et al.
BRIEFINGS IN BIOINFORMATICS (2018)
Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer
Alexa Montoya et al.
ONCOTARGET (2017)
Immunological consequences of immunization with tumor lysate vaccine and propranolol as an adjuvant: A study on cytokine profiles in breast tumor microenvironment
Somayeh Ashrafi et al.
IMMUNOLOGY LETTERS (2017)
G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts
Ernestina M. De Francesco et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage
A. Coats et al.
JOURNAL OF HUMAN HYPERTENSION (2017)
Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis
Hyun Yul Kim et al.
ONCOLOGY (2017)
Drug repurposing in cancer
Linda Sleire et al.
PHARMACOLOGICAL RESEARCH (2017)
Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study
G. Spera et al.
ANNALS OF ONCOLOGY (2017)
Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts
Rosamaria Lappano et al.
DRUGS (2017)
Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative
Zhihong Gong et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis
Sara Raimondi et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Repurposing of approved cardiovascular drugs
Junichi Ishida et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial
Takuma Higurashi et al.
LANCET ONCOLOGY (2016)
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Marc Hafner et al.
NATURE METHODS (2016)
Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma
Ludovic Jean Wrobel et al.
ONCOTARGET (2016)
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
Debora de Melo Gagliato et al.
ONCOTARGET (2016)
Repurposing metformin for cancer treatment: current clinical studies
Young Kwang Chae et al.
ONCOTARGET (2016)
Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer
Jun Hyoung Park et al.
CELL REPORTS (2016)
β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells
Jessica M. Wilson et al.
CANCER BIOLOGY & THERAPY (2015)
A Review of Nebivolol Pharmacology and Clinical Evidence
Justin Fongemie et al.
DRUGS (2015)
De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer
Adela Madrid-Paredes et al.
PHARMACOGENOMICS (2015)
Statins and cancers
Aleksandra Stryjkowska-Gora et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2015)
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies
Lang Wu et al.
SCIENTIFIC REPORTS (2015)
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
Eddy Pasquier et al.
Oncotarget (2015)
Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers
Forough Sanaee et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Monica Franciosi et al.
PLOS ONE (2013)
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials
Annemijn M. Algra et al.
LANCET ONCOLOGY (2012)
Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Hiroshi Noto et al.
PLOS ONE (2012)
Beta-adrenergic blocking drugs in breast cancer: a perspective review
Thomas I. Barron et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Lack of evidence that nebivolol is a β3-adrenoceptor agonist
Elfaridah P. Frazier et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
G protein-coupled receptors: novel targets for drug discovery in cancer
Rosamaria Lappano et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
beta 1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Catherine Huang et al.
BREAST CANCER RESEARCH (2011)
Nebivolol: the first vasodilatory beta-blocker with a β3-adrenergique agonist activity
C. Gauthier et al.
ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE (2010)
The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer
Erica K. Sloan et al.
CANCER RESEARCH (2010)
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Michael Bodmer et al.
DIABETES CARE (2010)
Statin use and cancer risk: a comprehensive review
Denise M. Boudreau et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines
Susan L. Holbeck et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Nebivolol, a Vasodilating Selective β1-Blocker, Is a β3-Adrenoceptor Agonist in the Nonfailing Transplanted Human Heart
Bertrand Rozec et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
Jack Cuzick et al.
LANCET ONCOLOGY (2009)
Nebivolol:: A highly selective β1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide
Sandeep Gupta et al.
CARDIOVASCULAR THERAPEUTICS (2008)
Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation
Angelo Maffei et al.
HYPERTENSION (2007)
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
Grazia Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
G-protein-coupled receptors and cancer
Robert T. Dorsam et al.
NATURE REVIEWS CANCER (2007)
Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries
James Inglese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
COX-2: A molecular target for colorectal cancer prevention
JR Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis
WWL Wong et al.
LEUKEMIA (2002)
分享论文
